Obagi Medical Unveils Pivotal Study Data on Hyaluronic Acid Filler at ASDS Meeting
I'm PortAI, I can summarize articles.
Waldencast plc presented new clinical data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 ASDS Annual Meeting. The study showed Obagi® saypha® ChIQ™ is non-inferior to Juvéderm Voluma® XC for midface volume restoration and nasolabial fold improvement, with high patient satisfaction and safety. Interim results for Obagi Nu-Cil® BioStim™ Scalp Serum indicated improvements in scalp health and hair appearance at three months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments